Prognostic Factors in Patients with Advanced HER2-Positive Gastric Cancer Treated with Trastuzumab-Based Chemotherapy: a Cohort Study

被引：0
|
作者：
Shoko Marshall
Takeru Wakatsuki
Daisuke Takahari
Tomohiro Matsushima
Naoki Ishizuka
Izuma Nakayama
Hiroki Osumi
Mariko Ogura
Takashi Ichimura
Eiji Shinozaki
Keisho Chin
Kensei Yamaguchi
机构：
[1] Tokyo Women’s Medical University Medical Center East,Department of Medicine
[2] Cancer Institute Hospital of the Japanese Foundation for Cancer Research,Department of Gastrointestinal Oncology
[3] Saitama Cancer Center,Department of Gastroenterology
[4] Department of Clinical Trial Planning and Management,undefined
[5] Clinical Research & Medical Development Center,undefined
来源：
Journal of Gastrointestinal Cancer | 2023年 / 54卷
关键词：
HER2; Gastric cancer; Trastuzumab; Prognostic factor; Visceral metastasis; Low hemoglobin; High LDH; High CRP;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：475 / 484
页数：9
相关论文
共 50 条
  • [41] Population pharmacokinetics of trastuzumab emtansine in previously treated patients with HER2-positive advanced gastric cancer (AGC)
    Shang-Chiung Chen
    Matts Kagedal
    Yuying Gao
    Bei Wang
    Marie-Laurence Harle-Yge
    Sandhya Girish
    Jin Jin
    Chunze Li
    Cancer Chemotherapy and Pharmacology, 2017, 80 : 1147 - 1159
  • [42] PTEN loss is a predictive marker for HER2-positive metastatic breast cancer patients treated with trastuzumab-based therapies
    Tekesin, Kemal
    Akar, Emre
    Gunes, Mehmet Emin
    Bayrak, Savas
    Ozturk, Tulin
    Altinay, Serdar
    Tural, Deniz
    JOURNAL OF BUON, 2019, 24 (05): : 1920 - 1926
  • [43] Mixed adenoneuroendocrine carcinoma with loss of HER2 positivity after trastuzumab-based chemotherapy for HER2-positive gastric cancer: a case report
    Hiromi Nagata
    Hironori Tsujimoto
    Yoshihisa Yaguchi
    Keita Kouzu
    Yujiro Itazaki
    Yusuke Ishibashi
    Satoshi Tsuchiya
    Takao Sugihara
    Nozomi Ito
    Manabu Harada
    Shinsuke Nomura
    Yoshitaka Utsumi
    Hideyuki Shimazaki
    Yoji Kishi
    Hideki Ueno
    Surgical Case Reports, 6
  • [44] HGCSG 1201: Phase II study of trastuzumab with irinotecan in HER2-positive metastatic or advanced gastric cancer patients previously treated with trastuzumab
    Kawamoto, Y.
    Yuki, S.
    Meguro, T.
    Hatanaka, K.
    Uebayashi, M.
    Iwanaga, I.
    Nakamura, M.
    Eto, K.
    Okuda, H.
    Abe, M.
    Aonuma, A.
    Abe, N.
    Sato, A.
    Nakatsumi, H.
    Muranaka, T.
    Yagisawa, M.
    Oba, K.
    Sakata, Y.
    Sakamoto, N.
    Komatsu, Y.
    ANNALS OF ONCOLOGY, 2017, 28
  • [45] Hormone-Receptor Expression and Activity of Trastuzumab-Based Therapy in HER2-Positive Advanced Breast Cancer Patients
    Montemurro, F.
    Rossi, V.
    Rocca, M. Cossu
    Martinello, R.
    Verri, E.
    Redana, S.
    Adamoli, L.
    Valabrega, G.
    Sapino, A.
    Aglietta, M.
    Viale, G.
    Goldhirsch, A.
    Nole, F.
    CANCER RESEARCH, 2010, 70
  • [46] HGCSG 1201: Phase II study of trastuzumab with irinotecan in HER2-positive metastatic or advanced gastric cancer patients previously treated with trastuzumab
    Takahide, Sasaki
    Yasuyuki, Kawamoto
    Satoshi, Yuki
    Takashi, Meguro
    Kazuteru, Hatanaka
    Minoru, Uebayashi
    Ichiro, Iwanaga
    Michio, Nakamura
    Kazunori, Eto
    Hiroyuki, Okuda
    Masakazu, Abe
    Ayane, Oba
    Nobuhiko, Abe
    Atsushi, Sato
    Hiroshi, Nakatsumi
    Kazuaki, Harada
    Tetsuhito, Muranaka
    Masataka, Yagisawa
    Koji, Oba
    Yuh, Sakata
    Yoshito, Komatsu
    ANNALS OF ONCOLOGY, 2017, 28
  • [47] Phase Ib Study of Buparlisib plus Trastuzumab in Patients with HER2-Positive Advanced or Metastatic Breast Cancer That Has Progressed on Trastuzumab-Based Therapy
    Saura, Cristina
    Bendell, Johanna
    Jerusalem, Guy
    Su, Shaun
    Ru, Qinhua
    De Buck, Stefan
    Mills, David
    Ruquet, Sophie
    Bosch, Ana
    Urruticoechea, Ander
    Beck, Joseph T.
    Di Tomaso, Emmanuelle
    Sternberg, David W.
    Massacesi, Cristian
    Hirawat, Samit
    Dirix, Luc
    Baselga, Jose
    CLINICAL CANCER RESEARCH, 2014, 20 (07) : 1935 - 1945
  • [48] Pertuzumab monotherapy following trastuzumab-based treatment: Activity and tolerability in patients with advanced HER2-positive breast cancer
    Cortes, J.
    Baselga, J.
    Petrella, T.
    Gelmon, K.
    Fumoleau, P.
    Verma, S.
    Pivot, X.
    Ross, G.
    Szado, T.
    Gianni, L.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [49] Phase II study of trastuzumab with irinotecan in HER2-positive gastric cancer previously treated with trastuzumab
    Hatanaka, Kazuteru
    Kawamoto, Yasuyuki
    Yuki, Satoshi
    Meguro, Takashi
    Uebayashi, Minoru
    Abe, Masakazu
    Nakamura, Michio
    Okuda, Hiroyuki
    Sakata, Yuh
    Komatsu, Yoshito
    ANNALS OF ONCOLOGY, 2017, 28
  • [50] HER2 Copy Number and Resistance Mechanisms in Patients with HER2-positive Advanced Gastric Cancer Receiving Initial Trastuzumab-based Therapy in JACOB Trial
    Pietrantonio, Filippo
    Manca, Paolo
    Bellomo, Sara Erika
    Corso, Simona
    Raimondi, Alessandra
    Berrino, Enrico
    Morano, Federica
    Migliore, Cristina
    Niger, Monica
    Castagnoli, Lorenzo
    Pupa, Serenella Maria
    Marchio, Caterina
    Di Bartolomeo, Maria
    Restuccia, Eleonora
    Lambertini, Chiara
    Tabernero, Josep
    Giordano, Silvia
    CLINICAL CANCER RESEARCH, 2023, 29 (03) : 571 - 580
12345